Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen Shoots Up Following Positive RENEW Results for Anti-LINGO-1

– First evidence of treatment-related remyelination in the human central nervous system –   – Ongoing SYNERGY trial will further inform potential for anti-LINGO-1 in MS –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study […]

Read More »

Major Diabetes Breakthrough Sets Stage for Human Clinical Trials

BALTIMORE, Apr. 15, 2015 /PRNewswire/ –Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new research update on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and […]

Read More »

AstraZeneca science is on the move, one year on from Pfizer bid

(Reuters) – Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move — quite literally.  As of last month, a four-days-a-week service set up by the drugmaker with Sun Air is connecting staff in its new Cambridge science and operations hub with […]

Read More »

Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the American Academy of Neurology (AAN) 2015 Annual Meeting

ALISO VIEJO, Calif., April 15, 2015 /PRNewswire/ — Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from the Phase 2 study of AVP-923 for the treatment of agitation in Alzheimer’s disease, data from the Alzheimer’s cohort of PRISM II of NUEDEXTA® for the treatment of Pseudobulbar […]

Read More »

Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin biosimilar) candidate

CRANBURY, N.J., April 15, 2015 /PRNewswire/ — Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study.  This study is currently being conducted at the Center for Human Drug Research (CHDR) in Leiden, […]

Read More »

Childhood trauma may raise risk of type 1 diabetes

Traumatic events during childhood may increase kids’ risk of developing type 1 diabetes, a Swedish study suggests. The researchers questioned more than 10,000 families and found that children who experienced an extremely stressful life event – like divorce, illness or death in the family – were about three times more likely to develop type 1 […]

Read More »

Approved Pfizer breast cancer drug impresses in latest study

The Pfizer logo is seen at their world headquarters in New York April 28, 2014. Reuters/Andrew Kelly Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients. […]

Read More »

ReSound Develops First Hearing Aid App for Apple Watch

COPENHAGEN, Denmark–(BUSINESS WIRE)–Today, ReSound introduced the first hearing aid app designed specifically for Apple Watch. Available immediately to Apple Watch wearers, the ReSound Smart™ app for Apple Watch offers a new, streamlined user experience, allowing users to take advantage of seamless, on-the-go control, right from their wrist. The ReSound Smart app for Apple Watch marks the latest of the company’s efforts to bring forward-looking solutions […]

Read More »

Marijuana Extract May Help Epilepsy Patients, Study

Medical Marijuana Extract Curbs Seizure Frequency In Early Trial Of Epilepsy Patients Epilepsy Researchers Hope to Replicate Promising Cannabidiol Findings in Randomized Controlled Studies A new study led by epilepsy specialists at NYU Langone Medical Center shows that some children and adults with treatment-resistant epilepsy may benefit from a treatment regimen including cannabidiol, a compound […]

Read More »

Heart chip beats toward better drug screening, personalized medicine

Reuters Health | Tue Apr 14, 2015 5:22pm EDT BY BEN GRUBER BERKELEY, CALIFORNIA – Bioengineers in California have developed a system that allows human heart cells to function outside the body, a development that could potentially prove a powerful tool  for drug development as well as pave the way toward personalizing treatments for patients with heart conditions. […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom